NCT03605056Unknown2 期
Chindamide in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma, a Phase II Trial
Peng Liu1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2018年7月31日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Response Rate
研究概览
简要总结
The purpose of this study is to evaluate the safety and effectiveness of combination of Chidamide-Lenalidomine-Dexamethasone in relapsed or refractory multiple myeloma patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patient ≥ age 18 years
- •Patient is able to understand and has given voluntary written informed consent before performance of any study-related procedures not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care
- •Patient has been previously diagnosed with MM based on standard International Myeloma Working Group (IMWG) criteria and currently requires treatment.
- •Patient must have received at least one previous line of therapy for multiple myeloma including bortezomib
- •Patient must have demonstrated disease progression on or within 60 days of completion of the last therapy. Patient has measurable disease defined as at least one of the following:
- •Serum M protein ≥ 0.5 g/dL (≥5 g/L)
- •Urine M protein ≥200 mg/24 hours
- •Serum free light chain (FLC) assay: Involved FLC assay ≥10 mg/dL (≥100 mg/L) and an abnormal serum FLC ratio (<0.26 or >1.65)
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤2
- •Negative serum or urine pregnancy test for women of child-bearing potential
- •Screening Laboratory parameters:
- •Absolute neutrophil count (ANC) ≥ 1,500 cells/dL (1.5 x 10^9/L). Granulocyte colony-stimulating factor (GCSF) is not permitted during screening to meet eligibility criteria and within 14 days of initiation of therapy
- •Platelet count ≥ 70,000 cells/dL (70 x 10^9/L) Platelet transfusion is not permitted during screening to meet eligibility criteria and within 14 days of initiation of therapy
- •Hemoglobin ≥ 8.0 g/dl ( red blood cell (RBC) transfusions are permitted during the screening period)
- •Total Bilirubin ≤ 1.5 X upper limit of normal (ULN) ; Aspartate transaminase (AST, or SGOT) and alanine transaminase (ALT, or SGPT) ≤ 2.5x ULN Estimated creatinine clearance by Cockcroft-Gault formula ≥ 50 mL/min
排除标准
- •Diagnosed or treated for another malignancy within 3 years prior to enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low risk prostate cancer after curative therapy.
- •Received any investigational drug within 14 days or 5 half-lives of the investigational drug, whichever is longer.
- •Prior anti-cancer therapy within 14 days.
- •Patient has any Grade 3 or > unresolved peripheral neuropathy from previous treatment.
- •Patient is human immunodeficiency virus (HIV) positive,.
- •Patient is Hepatitis B Surface antigen-positive or HBV-DNA copies > 10^3/ml
- •Patient has active hepatitis C infection.
- •Hypersensitivity to any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs
- •Known history of allergy to 2 or > drugs or any component of regimen
- •Any clinically significant, uncontrolled medical conditions that, in the treating Investigator's opinion, would impose excessive risk to the patient or may interfere with compliance or interpretation of the study results. Uncontrolled intercurrent illness may include, but is not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations as determined by treating investigator that would limit compliance with study requirements.
研究组 & 干预措施
CRD regimen
Experimental
CRD is a new 3-drug regimen adding a HDACi named chidamide to a novel 2-drug combination of lenalidomide and dexamethasone (RD)
干预措施: chidamide (Drug)
CRD regimen
Experimental
CRD is a new 3-drug regimen adding a HDACi named chidamide to a novel 2-drug combination of lenalidomide and dexamethasone (RD)
干预措施: lenalidomide (Drug)
CRD regimen
Experimental
CRD is a new 3-drug regimen adding a HDACi named chidamide to a novel 2-drug combination of lenalidomide and dexamethasone (RD)
干预措施: dexamethasone (Drug)
结局指标
主要结局
Response Rate
时间窗: 2 years
according to IMWG criteria, including the rate of complete remission (CR), very good partial remission (VGPR) and partial remission (PR)
次要结局
- Number of participants with treatment-related adverse events(2 years)
- Overall Survival Rate(2 years)
研究者
Peng Liu
Professor
Shanghai Zhongshan Hospital
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer PatientsTriple Negative Breast CancerNCT05632848Sun Yat-sen University47
招募中
不适用
Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell LymphomaDiffuse Large B Cell LymphomaNCT04432402The First Affiliated Hospital with Nanjing Medical University124
Unknown
2 期
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell LymphomaDiffuse Large B-cell LymphomaNCT02733380Henan Cancer Hospital20
已完成
1 期
Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLLAdult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARAAlkylating Agent-Related Acute Myeloid Leukemiade Novo Myelodysplastic SyndromePreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaSecondary Myelodysplastic SyndromeUntreated Adult Acute Myeloid LeukemiaNCT01132586National Cancer Institute (NCI)61
尚未招募
2 期
A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal CancerAdvanced Esophageal CarcinomaNCT06745193Peking University63